About one in five patients with multiple sclerosis don’t know their clinical phenotype – information that may help inform long-term treatment options for their disease, according to research presented at the 2020 virtual annual meeting of the Consortium of Multiple Sclerosis Centers.

About one in every three patients with multiple sclerosis (MS) uses complementary medicine in addition to conventional disease-modifying therapy.

Chronic active lesions in patients with multiple sclerosis (MS) are common, predict more aggressive disease, and occur despite disease-modifying therapy, according to a study of about 200 patients with MS.

Region- and lineage-specific transcriptomic changes appear to be responsible for the characteristic pathobiology of multiple sclerosis (MS).
A study that used single-nucleus RNA sequencing to assess changes in cell lineages in MS lesions has shed light on the selective cortical neuron damage and glial activation that contribute to the progression of MS lesions.

Stem cell therapy is a broad and multifarious field that, for multiple sclerosis (MS), is still experimental.

A pair of studies aims to determine whether early, aggressive treatment can improve long term outcomes for patients diagnosed with relapsing-remitting multiple sclerosis.

Neurologists and patients with multiple sclerosis are on the horns of a dilemma: How to best employ new disease-modifying drugs that are potent enough to induce life-changing remissions and too new to have amassed long-term safety data.